m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03470)
Name
ISIS 188782
Status
Investigative
TTD Drug ID
D0L0JX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Forkhead box protein O1A (FOXO1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188782. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ISIS 188782 through regulating the expression of Forkhead box protein O1A (FOXO1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188782. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 188782 through regulating the expression of Forkhead box protein O1A (FOXO1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188782. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188782 through regulating the expression of Forkhead box protein O1A (FOXO1). [2], [4]
References
Ref 1 Glucose Is Involved in the Dynamic Regulation of m6A in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2019 Mar 1;104(3):665-673. doi: 10.1210/jc.2018-00619.
Ref 2 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem. 2005 Sep 8;48(18):5639-43. doi: 10.1021/jm050392q.
Ref 3 METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. Theranostics. 2020 Jul 11;10(20):8939-8956. doi: 10.7150/thno.45178. eCollection 2020.
Ref 4 METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019 Oct 8;518(1):120-126. doi: 10.1016/j.bbrc.2019.08.018. Epub 2019 Aug 10.